Millennium Management’s Jasper Therapeutics JSPR Stock Holding History

Millennium Management’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-560	Closed	-$359K	–	6149
2024 Q4	$359K	Buy	+560	New	+$350K	﹤0.01%	4970

Other funds holding JSPR

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $8.36B AUM 14.46% 1-Year Est. Return

GSA Capital Partners London, United Kingdom $1.59B AUM 39.8% 1-Year Est. Return

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Millennium Management's JSPR Position: Q2 2026 in Review

Millennium Management reduced its Jasper Therapeutics (JSPR) stake by 70% in Q2 2026, selling an estimated $847K and leaving 16,231 shares worth $205K. The position accounts for ﹤0.01% of the portfolio, ranked #5306.

Millennium Management first reported a position in JSPR in Q1 2021 and has held it in 16 quarters since. The position peaked at $3.27M in Q1 2024. 43 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

Millennium Management held 16,231 shares of Jasper Therapeutics worth $205K as of Q2 2026.
Millennium Management sold 37,687 Jasper Therapeutics shares in Q2 2026, an estimated $847K.
Jasper Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q2 2026, its #5306 holding.
Millennium Management first reported a position in Jasper Therapeutics in Q1 2021 and has held it in 16 quarters since.
Millennium Management's Jasper Therapeutics position peaked at $3.27M in Q1 2024.
43 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.